Business
FDA Grants Fast Track Designation for Bexmarilimab
FDA Grants Fast Track Designation for Bexmarilimab.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n\nFaron Pharmaceuticals Ltd.\n \n(\"Faron\" or the \"Company\")\n \n \nInside Information: FDA Grants Fast Track Designation for Bexmarilimab in r/r MDS\n \nCompany announcement, Inside Information, 26 August 2024 at 7:00 a.m. BST / 9:00 a.m. EEST\n \nKey highlights\n- Given the strong data seen in Phase 1 and continuing in Phase 2 of Faron's BEXMAB trial, the FDA has granted Fast Track Designation (FTD) for bexmarilimab for the treatment of r/r MDS\n- FTD further strengthens the bexmarilimab program by offering clinical development and commercialization benefits\n \nTURKU, Finland - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER-1 receptor targeting approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumors, today announces that their lead candidate bexmarilimab has been granted Fast Track Designation for the treatment of relapsed or refractory myelodysplastic syndrome (r/r MDS) in combination with azacitidine by the USA Food and Drug Administration (the FDA).\n \nFast Track Designation is granted by the FDA for products that are intended for the treatment of serious or life-threatening disease or conditions, which demonstrate the potential to address an unmet medical need. The designation offers the opportunity for frequent interactions with the FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval, as well as eligibility for rolling submission of a New Drug Application.\n \nGiven the previously reported promising results in both Phase 1 and 2 of Faron's BEXMAB trial when treating r/r MDS patients using a combination of bexmarilimab and azacitidine to overcome primary or developed resistance to azacitidine, bexmarilimab has been granted Fast Track Designation subsequent to the accelerated development plan proposed by the FDA in July 2024. \"This news highlights the urgency for new treatment options besides HMAs for the treatment of higher-risk MDS and solidifies our case that bexmarilimab can overcome resistance to HMAs\", says Dr. Juho Jalkanen CEO of Faron. Relapsed or refractory myelodysplastic syndrome is an aggressive and deadly form o...